Table 2.
Summary of results in patients on VSL#3®
| Measurements | Mean pre-VSL#3® | Mean post-VSL#3® | p value |
|---|---|---|---|
| Systolic BP (mmHg) | 133 ± 13 | 130 ± 11 | 0.53 |
| Diastolic BP (mmHg) | 82 ± 8 | 80 ± 7 | 0.42 |
| Total cholesterol (mmol/l) | 4.51 ± 1.38 | 4.42 ± 1.27 | 0.83 |
| HDL (mmol/l) | 1.07 ± 0.26 | 1.09 ± 0.24 | 0.79 |
| LDL (mmol/l) | 2.58 ± 1.18 | 2.56 ± 1.02 | 0.95 |
| Triglycerides (mmol/l) | 1.89 ± 0.57 | 1.91 ± 1.00 | 0.94 |
| HbA1c (mmol/mol) | 54 ± 12 | 55 ± 12 | 0.87 |
| Fructosamine (μmol/l) | 257 ± 44 | 263 ± 49 | 0.67 |
| HOMA-IR | 2.2 ± 1.9 | 2.2 ± 1.5 | 0.95 |
| ∆RI-GTN (%) | 28 ± 6 | 25 ± 8 | 0.20 |
| ∆RI-Salb (%) | 9 ± 8 | 8 ± 4 | 0.62 |
| sVCAM-1 (ng/ml) | 536 ± 305 | 524 ± 262 | 0.90 |
| cGMP (pmol/l) | 178 ± 57 | 159 ± 43 | 0.27 |
| Blood glutathione ratio | 22 ± 10 | 26 ± 13 | 0.21 |
| TAC [mM Asc (AEAC)] | 0.46 ± 0.04 | 0.47 ± 0.07 | 0.75 |
| hsCRP (mg/l) | 3.0 ± 2.5 | 3.9 ± 6.1 | 0.53 |
| ALT (iu/l) | 56 ± 31 | 51 ± 32 | 0.63 |
| AST (iu/l) | 40 ± 16 | 38 ± 20 | 0.78 |
| Mode ASQ (C2m) | 91 ± 14 | 95 ± 16 | 0.57 |
VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo group and 1 from VSL#3® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed ASQ (10 in VSL#3® group and 11 in placebo group). Missing data were excluded from respective analyses